Cytotoxicity and Cell Cycle Effects of Novel Indolo[2,3-b]quinoline Derivatives

Oncology Research

Volumn 13, Issue 5, 2002, Pages 269-277

  Humeniuk, Rita ^a   Kaczmarek, Łukasz ^b   Peczyńska Czoch, Wanda ^c   Marcinkowska, Ewa ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b Pharmaceutical Research Institute   (Poland)

^c WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Apoptosis; Cell cycle; Cytotoxicity; Etoposide; Indoloquinolines; Topoisomerase II

Indexed keywords

11 METHYLNEOCRYPTOLEPINE; 2 METHOXY 5,9,11 TRIMETHYL 5H INDOLO[2,3 B]QUINOLINE; 2,5,9,11 TETRAMETHYL 5H INDOLO[2,3 B]QUINOLINE; 2,9 DIMETHOXY 5,11 DIMETHYL 5H INDOLO[2,3 B]QUINOLINE; 9 METHOXY 2,5,11 TRIMETHYL 5H INDOLO[2,3 B]QUINOLINE; ALKALOID; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; INDOLOQUINOLINE DERIVATIVE; INDOLO[2,3 B]QUINOLINE; NEOCRYPTOLEPINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; QUINOLINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYPTOLEPIS; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL STRAIN HL 60; DOSE RESPONSE; LEUKEMIA CELL LINE; PHYSIOLOGY;

ALKALOIDS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE; DOSE-RESPONSE RELATIONSHIP, DRUG; HL-60 CELLS; HUMANS; JURKAT CELLS; QUINOLINES;

EID: 0141958578     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504003108748320     Document Type: Article

References (27)

1. Boye, L. G.; Oku-Ampofo, O. Medicinal plants in Ghana. In: Wagner, H.; Hikino, H.; Farnsworth, N. R., eds. Economic and medicinal plant research, vol. 4: Plants and traditional medicine. London: Academic Press; 1990:32-33.
2. Peczyńska-Czoch, W.; Mordarski, M.; Kaczmarek, Ł.; Nantka-Namirski, P. Biotransformation of azacarbazoles as a means of development of novel antineoplastic compounds. In: Bushel, M. R.; Grafe, U., eds. Progress in industrial microbiology (Vol. 27). Amsterdam: Elsevier; 1989:333-353.
3. Peczyńska-Czoch, W.; Pognan, F.; Kaczmarek, Ł.; Boratyński, J. Synthesis and structure-activity relationship of methyl-substituted indolo[2,3-b]quinolines: Novel cytotoxic, DNA topoisomerase II inhibitors. J. Med. Chem. 37:3503-3510; 1994.
4. Cimanga, K.; De Bruyne, T.; Pieters, L.; Claeys, M.; Vietinck, A. New alkaloids from Cryptolepis sanguinolenta. Tetrahedron Lett. 37:1703-1706; 1996.
5. Bonjean, K.; De Pauw-Gillet, M.-C.; Defresne, M.-P.; Colson P.; Houssier, C.; Dassonneville, L.; Bailly, C.; Greimers, R.; Wright, C.; Quetin-Leclerq, J.; Angenot, L. Cryptolepine is a potent DNA intercalating agent which inhibits selectively DNA synthesis in B16 melanoma cells cultured in vitro. Anticancer Res. 17:4068-4069; 1998.
6. Dassonneville, L.; Bonjean, K.; De Pauw-Gillet, M. C.; Colson, P.; Houssier, C.; Quetin-Leclerq, J.; Angenot, L.; Bailly, C. Stimulation of topoisomerase II-mediated DNA cleavage by three DNA-intercalating plant alkaloids: Cryptolepine, matadine and serpentine. Biochemistry 38:7719-7726; 1999.
7. Bailly, C.; Laine, W.; Baldeyrou, B.; De Pauw-Gillet, M.-C.; Colson, P.; Houssier, C.; Cimanga, K.; Van Miert, S.; Vlietinck, A. J.; Pieters, L. DNA intercalation, topoisomerase II inhibition and cytotoxic activity of plant alkaloid neocryptolepine. Anticancer Drug Des. 15:191-201; 2000.
8. Kaczmarek, Ł.; Peczyńska-Czoch, W.; Osiadacz, J.; Mordarski, M.; Sokalski, W. A.; Boratyński, J.; Marcinkowska, E.; Glazman-Kuśnierczyk, H.; Radzikowski, C. Synthesis, and cytotoxic activity of some novel indolo[2,3-b]quinoline derivatives: DNA topoisomerase II inhibitors. Bioorg. Med. Chem. 7:2457-2464; 1999.
9. Pognan, F.; Saucier, J.-M.; Paoletti, C.; Kaczmarek, Ł.; Nantka-Namirski, P.; Mordarski, M.; Peczyńska-Czoch, W. A carboline derivative as a novel mammalian DNA topoisomerase II targeting agent. Biochem. Pharmacol. 44:2149-2155; 1992.
10. Osiadacz, J.; Majka, J.; Czarnecki, K.; Peczyńska-Czoch, W.; Zakrzewska-Czerwińska, J.; Kaczmarek, Ł.; Sokalski, W. A. Sequence-selectivity of 5,11-dimethyl-5H-indolo[2,3-b]quinoline binding to DNA. Footprinting and molecular modeling studies. Bioorg. Med. Chem. 8:937-943; 2000.
11. Harker, W. G.; Slade, D. L.; Drake, F. H.; Parr, R. L. Mitoxantrone resistance in HL-60 leukemia cells: Reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry 30:9953-9961; 1991.
12. Kaufmann, S. H.; Earnshaw, W. C. Induction of apoptosis by cancer chemotherapy. Exp. Cell Res. 256:42-49; 2000.
13. Mesner, P.; Budihardjo, I.; Kaufmann, S. H. Chemotherapy-induced apoptosis. Adv. Pharmacol. 41:461-499; 1997.
14. Li, X.; Gong, J.; Feldman, E.; Seiter, K.; Traganos, F.; Darzynkiewicz, Z. Apoptotic cell death during treatment of leukemias. Leuk. Lymphoma 13:65-70; 1994.
15. Friesen, C.; Herr, I.; Krammer, P. H.; Debatin, K.-M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug induced apoptosis in leukemia cells. Nat. Med. 2:574-577; 1996.
16. Friesen, C.; Fulda, S.; Debatin, K.-M. Deficient activation of the CD95 (APO-1/FAS) system in drug-resistant cells. Leukemia 11:1833-1841; 1997.
17. Fulda, S.; Sieverts, H.; Friesen, C.; Herr, I.; Debatin, K.-M. The CD95 (APO-1/FAS) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 57: 3823-3829; 1997.
18. Reed, J. C. Mechanisms of apoptosis avoidance in cancer. Curr. Opin. Oncol. 11:68-75; 1999.
19. Kroemer, G.; Reed, J. C. Mitochondrial control of cell death. Nat. Med. 6:513-519; 2000.
20. Zhang, L.; Yu, J.; Park, B. H.; Kinzler, K. W.; Vogelstein, B. Role of BAX in the apoptotic response to anticancer agents. Science 290:989-992; 2000.
21. Kaufmann, S. H. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin and other cytotoxic anticancer drugs: A cautionary note. Cancer Res. 49:5870-5878; 1989.
22. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63; 1983.
23. Darzynkiewicz, Z.; Li, X.; Bedner, E. Use of flow and laser-scanning cytometry in analysis of cell-death. VIII. DNA fragmentation assay: Detection of cells with fractional ("subdiploid") DNA content. Methods Cell Biol. 66:87-90; 2001.
24. Dassonneville, L.; Lansiaux, A.; Wattelet, A.; Wattez, N.; Mahieu, C.; Van Miert, S.; Pieters, L.; Bailly, C. Cytotoxicity and cell cycle effects of the plant alkaloids cryptolepine and neocryptolepine: Relation to drug-induced apoptosis. Eur. J. Pharm. 409:9-18; 2000.
25. Ishiyama, K.; Satoh, S.; Igarashi, Y.; Kumagai, H.; Yahagi, A.; Sasaki, H. Flow cytometric analysis of the cell cycle of the leukemic cell lines treated with etoposide and cytosine arabinoside. Tohoku J. Exp. Med. 174: 95-107; 1994.
26. Osiadacz, J.; Kaczmarek, L.; Opolski, A.; Wietrzyk, J.; Marcinkowska, E. ; Biernacka, K.; Radzikowski, C.; Jon, M.; Peczyńska-Czoch, W. Microbial conversion of methyl- and methoxy-substituted derivatives of 5H-indolo[2,3-b]quinoline as a method of developing novel cytotoxic agents. Anticancer Res. 19:3333-3342; 1999.
27. Kaufmann, S. H. Cell death induced by topoisomerase-targeted drugs: More questions than answers. Biochim. Biophys. Acta 1400:195-211; 1998.